Pharmaceutical preparations for use in the treatment of seizures, bipolar disorders, depression, amyotrophic lateral sclerosis, migraines, Parkinson's disease, neurofibromatosis, chronic obstructive pulmonary disease, and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the prevention and treatment of central nervous system disorders, neurological diseases and disorders, neurodegenerative disorders, depression and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the treatment of seizures in epilepsy, mood changes in bipolar disorders and depression, reduction in symptoms associated with amyotrophic lateral sclerosis, migraines, Parkinson's disease, and ophthalmology-related disorders including dry eye and glaucoma, chronic obstructive pulmonary disease, and lesion reduction in neurofibromatosis, each administered via drug delivery agents in the form of liquids, extended-release oral solids, inhalation, liquid nasal sprays, powder nasal sprays, and topical formulations that facilitate the delivery of pharmaceutical preparations.